Compounded bioidentical menopausal hormone therapy – a physician perspective

References

• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause 2017;24:728–53
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric 2016;19:313–15
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2015;100:3975–4011
   PubMed Web of Science ®Google Scholar
• Sarri G, Davies M, Lumsden MA. Diagnosis and management of menopause: summary of NICE guidance. BMJ 2015;351:h5746
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353–68
   PubMed Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, WHI Investigators, et al. Menopausal hormone therapy and long-term all-cause and cause-specific Mortality: the women's health initiative randomized trials. JAMA 2017;318:927–38
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199–208
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014;161:249–60
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016;374:1221–30
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Conner EA. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric 2019;22:140–7
   PubMed Web of Science ®Google Scholar
• Lobo RA, Archer DF, Kagan R, et al. A 17B-estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2018;132:161–70
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Pickar JH. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy. Menopause 2016;23:215–23
   PubMed Web of Science ®Google Scholar
• Santoro N, Braunstein GD, Butts CL, et al. Compounded bioidentical hormones in endocrinology practice: an endocrine society scientific statement. J Clin Endocrinol Metab 2016;101:1318–43
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women’s Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–4
   PubMed Web of Science ®Google Scholar
• Steinkellner AR, Denison SE, Eldridge SL, et al. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause 2012;19:616–21
   PubMed Web of Science ®Google Scholar
• Crawford SL, Crandall CJ, Derby CA, et al. Menopausal hormone therapy trends before versus after 2002: impact of the Women’s Health Initiative Study results. Menopause 2019;26:588–97
   Web of Science ®Google Scholar
• Weissfeld JL, Liu W, Woods C, et al. Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance. Menopause 2018;25:611–14
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Gill TK, Broadbent JL, et al. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009;12:122–30
   PubMed Web of Science ®Google Scholar
• Farmer R, Fenton A. Time trends in breast cancer and menopause hormone therapy use in New Zealand. Climacteric 2016;19:42–8
   PubMed Web of Science ®Google Scholar
• Natari RB, McGuire TM, Baker PJ, et al. Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia. Climacteric 2019;22:489–97
   PubMed Web of Science ®Google Scholar
• Clarkson TB. Progestogens and cardiovascular disease. A critical review. J Reprod Med 1999;44:180–4
   PubMed Web of Science ®Google Scholar
• Yuksel N, Treseng L, Malik B, et al. Promotion and marketing of bioidentical hormone therapy on the internet: a content analysis of websites. Menopause 2017;24:1129–35
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. Washington, DC: The National Academies Press; 2020
   Google Scholar
• Davis SR, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women. Climacteric 2019;22:429–34
   PubMed Web of Science ®Google Scholar
• McPherson T, Fontane P, Bilger R. Patient experiences with compounded medications. J Am Pharm Assoc (2003) 2019;59:670–7
   PubMed Web of Science ®Google Scholar
• Thompson JJ, Ritenbaugh C, Nichter M. Why women choose compounded bioidentical hormone therapy: lessons from a qualitative study of menopausal decision-making. BMC Womens Health 2017;17:97
   PubMed Web of Science ®Google Scholar
• Constantine GD, Archer DF, Graham S, et al. Prescribing of FDA-approved and compounded hormone therapy differs by specialty. Menopause 2016;23:1075–82
   PubMed Web of Science ®Google Scholar
• Fishman JR, Flatt MA, Settersten RA. Jr. Bioidentical hormones, menopausal women, and the lure of the “natural” in U.S. anti-aging medicine. Soc Sci Med 2015;132:79–87
   PubMed Web of Science ®Google Scholar
• Dubaut JP, Dong F, Tjaden BL, et al. Prescribing bioidentical menopausal hormone therapy: a survey of physician views and practices. J Womens Health (Larchmt) 2018;27:859–66
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Santoro N. Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women. Menopause 2015;22:926–36
   PubMed Web of Science ®Google Scholar
• Gass ML, Stuenkel CA, Utian WH, et al. Use of compounded hormone therapy in the United States: report of the North American Menopause Society survey. Menopause 2015;22:1276–84
   PubMed Web of Science ®Google Scholar
• Files JA, Kransdorf LN, Ko M, et al. Bioidentical hormone therapy: an assessment of provider knowledge. Maturitas 2016;94:46–51
   PubMed Web of Science ®Google Scholar
• Outterson K. Regulating compounding pharmacies after NECC. N Engl J Med 2012;367:1969–072
   PubMed Web of Science ®Google Scholar
• Drazen JM, Curfman GD, Baden LR, Morrissey S. Compounding errors. N Engl J Med 2012;367:2436–7
   PubMed Web of Science ®Google Scholar
• Outterson K. The drug quality and security act-mind the gaps. N Engl J Med 2014;370:97–9
   PubMed Web of Science ®Google Scholar
• FD&C Act Provisions that apply to human drug compounding. Current 14 Jul 2020. Available from: www.fda.gov/drugs/human-drug-compounding/fdc-act-provisions-apply-human-drug-compounding [accessed 21 Jul 2020]
   Google Scholar
• Woodcock J, Dohm J. Toward better-quality compounded drugs – an update from the FDA. N Engl J Med 2017;377:2509–12
   PubMed Web of Science ®Google Scholar
• FDA’s Human Drug Compounding Progress Report: Three years after enactment of the drug quality and security act. January 2017. Available from: www.fda.gov/media/102493/download [accessed 29 Jul 2020]
   Google Scholar
• The Pew Charitable Trusts. 2016. National assessment of state oversight of sterile drug compounding. https://www.pewtrusts.org/∼/media/assets/2016/02/national_assessment_of_state_oversight_of_sterile_drug_compounding.pdf [accessed 9 Jan 2020]
   Google Scholar
• The Pew Charitable Trusts and NABP (National Association of Boards of Pharmacy). State oversight of drug compounding. Major progress since 2015, but opportunities remain to better protect patients. 2018. Available from: https://www.pewtrusts.org/en/research-and-analysis/reports/2018/02/state-oversight-of-drug-compounding [accessed 5 Feb 2020]
   Google Scholar
• Stuenkel CA, Manson JE. Compounded bioidentical hormone therapy: does the regulatory double standard harm women? JAMA Intern Med 2017;177:1719–20
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Constantine GD. Compounded non-FDA-approved menopausal hormone therapy prescriptions have increased: results of a pharmacy survey. Menopause 2016;23:359–67
   PubMed Web of Science ®Google Scholar
• Worsley R, Bell RJ, Gartoulla P, Davis SR. Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women. Menopause 2016;23:11–17
   PubMed Web of Science ®Google Scholar
• Iftikhar S, Shuster LT, Johnson RE, Jenkins SM, Wahner-Roedler DL. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchm) 2011;20:559–65
   PubMed Web of Science ®Google Scholar
• Ramin CJ. The hormone hoax thousands fall for. Available from: https://static1.squarespace.com/static/5821fcda579fb3ff43e5876c/t/58ae0bc41b10e3128533d7d4/1487801284953/MORE-Hormone-Hoax.pdf [accessed 20 Jul 2020]
   Google Scholar
• Stanczyk FZ, Niu C, Azen C, Mirkin S, Amadio JM. Determination of estradiol and progesterone content in capsules and creams from compounding pharmacies. Menopause 2019;26:966–71
   PubMed Web of Science ®Google Scholar
• Constantine GD, Kessler G, Graham S, Goldstein SR. Increased incidence of endometrial cancer following the Women's Health Initiative: an assessment of risk factors. J Womens Health (Larchmt) 2019;28:237–43
   PubMed Web of Science ®Google Scholar
• Jiang X, Postmenopausal pellet vs. FDA approved hormonal therapy: an assessment of serum estradiol and testosterone levels. Abstract S-14. North American Menopause Society Annual Meeting; 2019 Sep 25–28; Chicago, IL
   Google Scholar
• Seaborg E. Targeting patients with pellets: a look at bioidentical hormones. October 2019. Available from: https://endocrinenews.endocrine.org/targeting-patients-with-pellets-a-look-at-bioidentical-hormones [accessed 21 Jul 2020]
   Google Scholar
• Dohm J, Kim J, Woodcock J. Improving adverse event reporting for compounded drugs. JAMA Intern Med 2019;179:1461–2
   PubMed Web of Science ®Google Scholar
• De Pinho JC, Aghajanova L, Herndon CN. Prepubertal gynecomastia due to indirect exposure to nonformulary bioidentical hormonal replacement therapy: a case report. J Reprod Med 2016;61:73–7
   PubMed Web of Science ®Google Scholar
• Franklin SL. Effects of unintentional exposure of children to compounded transdermal sex hormone therapy. Pediatr Endocrinol Rev 2011;8:208–12
   PubMedGoogle Scholar
• Felner EI, White PC. Prepubertal gynecomastia: indirect exposure to estrogen cream. Pediatrics 2000;105:E55
   PubMed Web of Science ®Google Scholar
• Schwarze RA, Threlfall WR. Theriogenology question of the month. Follicular cysts. J Am Vet Med Assoc 2008;233:235–7
   PubMedGoogle Scholar
• Lau E. Hormone replacement skin products affect users’ pets, confound veterinarians. Available from: http://news.vin.com/VINNews.aspx?articleID=115950
   Google Scholar
• Stuenkel CA, Pion PD, Lau E, Inadvertent transfer of cutaneous estrogens from women to cats and dogs. P1-326. 93rd Annual Meeting of The Endocrine Society; 2011 Jun 4–7; Boston, MA
   Google Scholar
• Stuenkel CA, Gass MLS, Results from 2010 NAMS Survey on Secondary Transfer of Transdermal Estrogen Preparations. P-85. The North American Menopause Society’s 22nd Annual Meeting; 2011 Sep 21–24; Washington, DC
   Google Scholar
• Grant MD, Marbella A, Wang AT. Menopausal symptoms: comparative effectiveness of therapies. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015. Mar Report no.: 15-EHC005-EF. AHRQ Comparative Effectiveness Reviews
   Google Scholar
• US Food and Drug Administration. FDA announces new and expanded compounding research projects [press release]. September 26, 2018. Available from: www.fda.gov/Drugs/DrugSafety/ucm621776.html [Updated 3 Oct, 2018; accessed 21 Jul 2020]
   Google Scholar
• Cobin RH, Goodman NF. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on MENOPAUSE-2017 UPDATE. Endocr Pract 2017;23:869–80
   PubMed Web of Science ®Google Scholar
• McBane SE, Borgelt LM, Barnes KN, et al. Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2014;34:410–23
   PubMed Web of Science ®Google Scholar
• McBane SE, Coon SA, Anderson KC, et al. American College of Clinical Pharmacy. Rational and irrational use of nonsterile compounded medications. J Am Coll Clin Pharm 2019;2:189–97
   Google Scholar
• American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Committee opinion number 532. Compounded bioidentical menopausal hormone therapy. 2012; Reaffirmed 2020
   Google Scholar
• American Medical Association. Hormone therapies: Off-label uses and unapproved formulations (resolution 512-a-15). Chicago, IL: American Medical Association; 2016. Available from: https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/2016-interim-csaph-report-4.pdf [accessed 11 Aug 2020]
   Google Scholar
• Endocrine Society Position Statement. Compounded bioidentical hormone therapy, September. 2019. https://www.endocrine.org/-/media/endocrine/files/advocacy/positionstatement/position_statement_compound_biomedical_hormone_therapy.pdf [accessed 11 Aug 2020]
   Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• British Menopause Society. Bioidentical HRT. 2019. https://thebms.org.uk/publications/consensus-statements-bioidentical-hrt [accessed 17 Apr 2020]
   Google Scholar
• Neves-e-Castro M, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas 2015;81:88–92
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Menopause: diagnosis and management. Published 12 November 2015. Last updated 5 December 2019. https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-pdf-1837330217413 [accessed 14 Aug 2020]
   Google Scholar
• Guidozzi F, Alperstein A, Bagratee JS, et al. South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014. S Afr Med J 2014;104:537–43
   PubMed Web of Science ®Google Scholar
• Baron RJ, Berinsky AJ. Mistrust in science – a threat to the patient-physician relationship. N Engl J Med 2019;381:182–5
   PubMed Web of Science ®Google Scholar